ONKOLOGIK BEMORLARDA YURAK-QON TOMIR KASALLIKLARI
##article.subject##:
kimyoterapiya, kardiotoksiklik, miokard disfunksiyasi va yurak yetishmovchiligi, aritmiya, ishemiya, erta aniqlash, kuzatish##article.abstract##
Yurak - qon tomir kasalliklarining rivojlanishi (YuQTK) saratonga qarshi davolanishning yurak faoliyati va tuzilishiga toksik ta'siri natijasida yoki mavjud yurak-qon tomir xavf omillari bilan YuQTK rivojlanishining tezlashishi natijasida onkopatologiyasi bo'lgan bemorlarni davolashda eng ko'p uchraydigan nojo'ya ta'sirlarni anglatadi. Maqolada 2016 yilda saraton va yurak-qon tomir toksikligini davolash bo'yicha EOS ko'rsatmalariga asoslanib, saratonga qarshi davolanishni tayinlashdan oldin, jarayonida va tugaganidan keyin yurak-qon tomir tizimining ishlashini kuzatish va qaror qabul qilishning turli bosqichlari batafsil ko'rib chiqilgan.
Библиографические ссылки
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines / The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) // Eur. Heart. J. – 2016. – Vol. 21, № 37 (36). – Р. 2768–2801.
E. T. Yeh, C. L. Bickford. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management / // J. Am. Coll. Cardiol. – 2009. – № 53. – Р. 2231–2247.
J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent [et al.]Cancer incidence and mortality patterns in Europe:estimates for 40 countries in 2012. // Eur. J. Cancer.2013. –№ 49. – Р. 1374–1403.
K.C. Oeffinger, A. C. Mertens, C. A. Sklar [et al.]Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer / // N. Engl. J. Med. – 2006. – № 355. – 1572–1582.
Limat, E. Daguindau, J. Y. Cahn [et al.]. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma / S// J. Clin. Pharm. Ther. – 2014. – № 39. – Р. 168–174.
M.G. Khouri, P. S. Douglas, J. R. Mackey [et al.]Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues / // Circulation 2012. – № 126. – Р. 2749–2763.
M.S. Ewer, S. M. Ewer Ewer M. S. Cardiotoxicity of anticancer treatments / // Nat Rev Cardiol. – 2015. – № 12. – Р. 620.
P.S. Hall, L. C. Harshman, S. Srinivas, R. M. Witteles. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients / // JACC Heart Fail. – 2013. – № 1. – Р. 72–78.
R. Siegel, C. DeSantis, K. Virgo [et al.]Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. –2012. – № 62. – Р. 220–241.
S.M. Swain, F. S. Whaley, M. S. Ewer. Swain S. M. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials / // Cancer. – 2003. – № 97. – Р. 2869–2879.
